Brief: Champions Oncology Q1 Adjusted EPS USD 0.02

Champions Oncology

15/09/2025 20:55

Overview

Champions Oncology fiscal Q1 revenue of $14 mln

The cancer-focused R&D firm's adjusted EPS for fiscal Q1 at $0.02

Outlook

Champions Oncology expects topline expansion and margin improvement in FY 2026

Company anticipates reduced cost of sales as lab work is internalized

Champions Oncology sees growing demand for proprietary data offerings

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$14 mln
$13.50 mln (1 Analyst)
Q1 Adjusted EPS
Beat
$0.02
-$0.01 (1 Analyst)
Q1 EPS
-$0.03


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 43.1% above its September 12 closing price of $6.83

Press Release: ID:nACS7PC4ta

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)